Amy L. Abate
Amy L. Abate received her bachelor’s degree in 2001 from Boston College (B.A., Economics, with a minor in Italian), graduating cum laude, and received her J.D. in 2005 from Brooklyn Law School, where she was a member of the Brooklyn Journal of International Law.
Ms. Abate concentrates her practice on mass tort litigation and is involved in an array of pharmaceutical and consumer injury cases. She is currently investigating cases involving defective DePuy ASR hip replacement devices, as well as cases concerning Accutane, Fosamax, denture cream, Yasmin, and transvaginal mesh.
Ms. Abate has worked on several securities fraud class actions against numerous issuers of securities for allegedly misleading investors, including: In re Marsh & McLennan Cos., Inc. Securities Litigation, No. 04-CV-8144 (CM) (S.D.N.Y.) ($400 million recovery); and In re Royal Dutch/Shell Transport Securities Litigation, No. 04-374 (JAP) (D.N.J.) (U.S. settlement with a minimum cash value of $138.3 million and a contingent value of more than $180 million, in addition to a $350 million European settlement that the Firm was substantially responsible for obtaining).
Ms. Abate has also worked on antitrust and consumer class action matters, including In re Rail Freight Fuel Surcharge Antitrust Litigation, No. 07 MC 0489 (D.D.C.).
Ms. Abate recently co-authored “Schleicher v. Wendt Impact: The Seventh Circuit Splits with the Fifth Circuit on Class Certification Requirements,” Securities Litigation Report (with Partner Jeffrey M. Haber), October 2010.
Ms. Abate is admitted to the Bars of the States of New York and Connecticut.
